Skip to main content
Ascletis Pharma Inc. logo

Ascletis Pharma Inc. — Investor Relations & Filings

Ticker · 1672 ISIN · KYG0520K1094 LEI · 254900SKEFCO9I3GPL05 HKEX Manufacturing
Open in API
Filings indexed 1,468 across all filing types
Latest filing 2026-04-30 Regulatory Filings
Country KY Cayman Islands
Listing HKEX 1672

About Ascletis Pharma Inc.

http://www.ascletis.com

Ascletis Pharma Inc. is a fully integrated, R&D driven biotechnology company dedicated to the development and commercialization of potential best-in-class and first-in-class therapeutics. The company covers the entire value chain from discovery to sales. Ascletis primarily focuses on metabolic diseases, including chronic weight management, utilizing proprietary platforms such as Artificial Intelligence-assisted Structure-Based Drug Discovery (AISBDD), Ultra-Long-Acting Platform (ULAP), and Peptide Oral Transport ENhancement Technology (POTENT). Key pipeline candidates include ASC30 (oral/subcutaneous GLP-1R agonist), ASC35 (GLP-1R/GIPR dual agonist), ASC36 (amylin receptor agonist), and ASC37 (GLP-1R/GIPR/GCGR triple agonist). The company also maintains active programs in viral diseases, NASH/PBC, and oncology.

Recent filings

Filing Released Lang Actions
VOLUNTARY ANNOUNCEMENT - ASCLETIS TO PRESENT DATA ON MULTIPLE PROGRAMS AT THE AMERICAN DIABETES ASSOCIATION'S 2026 SCIENTIFIC SESSIONS
Regulatory Filings Classification · 1% confidence The document is a voluntary corporate announcement on HKEx informing shareholders and investors that Ascletis Pharma will present scientific data at the ADA 2026 conference. It does not contain financial results, meeting materials, dividend notices, or any detailed report; it’s a general corporate event announcement. No specific category for scientific conference events exists, so it falls under Regulatory Filings (RNS) as the fallback for miscellaneous announcements.
2026-04-30 English
Annual Report 2025
Regulatory Filings
2026-04-29 English
VOLUNTARY ANNOUNCEMENT - ASCLETIS COMPLETES ENROLLMENT IN U.S. PHASE II STUDY OF ASC30, AN ORAL SMALL MOLECULE GLP-1R AGONIST, FOR THE TREATMENT OF DIABETES
Regulatory Filings Classification · 1% confidence The document is a voluntary business update announcement regarding the completion of enrollment in a clinical trial, filed on the Hong Kong Exchange as a regulatory announcement rather than a financial report, earnings release, or specific governance/transaction notice. It does not present financial results (ER/IR), management changes (MANG), capital transactions (CAP/SHA/POS), voting results (DVA), or other specific categories. It therefore falls under the general “Regulatory Filings” fallback category (RNS).
2026-04-27 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 March 2026
Regulatory Filings Classification · 1% confidence The document is a Form FF301 “Monthly Return for Equity Issuer and Hong Kong Depositary Receipts” submitted to the HKEX under Chapter 19B of the Listing Rules, detailing authorized share capital, issued and treasury share movements, share options, repurchases, and public float confirmations for the month ended 31 March 2026. This is a routine monthly regulatory compliance filing rather than an annual report, earnings announcement, management discussion, or specific capital financing update. It does not introduce a single new share issue or stock split announcement (which would be SHA), nor is it a standalone share repurchase notice (POS). Therefore it falls under the miscellaneous Regulatory Filings category (RNS).
2026-04-08 English
VOLUNTARY ANNOUNCEMENT - ASCLETIS ANNOUNCES FIXED-DOSE COMBINATION OF ASC30, ONCE-DAILY ORAL SMALL MOLECULE GLP-1R AGONIST, AND ASC39, ONCE-DAILY ORAL SMALL MOLECULE AMYLIN-SELECTIVE AMYLIN RECEPTOR
Regulatory Filings
2026-04-07 English
ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2025 AND CHANGE IN THE USE OF PROCEEDS
Earnings Release Classification · 1% confidence The document is titled “ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2025,” presented as an official announcement on the Hong Kong Stock Exchange. It contains audited condensed consolidated annual results, key financial highlights (income, expenses, loss per share), a corporate profile, detailed pipeline updates, and a Management Discussion and Analysis section. This format aligns with an initial public announcement of full-year financial results rather than the complete statutory annual report (10-K) or a proxy, governance, or regulatory filing. Therefore, it should be classified as an Earnings Release (ER). FY 2025
2026-03-31 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.